23 results
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company NV
8 May 24
Quarterly report
4:30pm
result in information theft, compromise, or other unauthorized access, data corruption and significant disruption of our business operations … Act, and other state and national anti-bribery and anti-money laundering laws in the jurisdictions in which we conduct activities. Anti-corruption
10-K
2023 FY
NAMS
NewAmsterdam Pharma Company NV
28 Feb 24
Annual report
8:00am
or consultants, could result in information theft, compromise, or other unauthorized access, data corruption and significant disruption of our business … conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other
8-K
EX-1.1
NAMS
NewAmsterdam Pharma Company NV
15 Feb 24
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
4:18pm
in the Registration Statement, the Time of Sale Prospectus or the Prospectus.
(ll) Anti-Corruption and Anti-Bribery Laws. Neither the Company nor any … Corrupt Practices Act of 1977, as amended (the “FCPA”), the UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law
F-3
EX-1.2
NAMS
NewAmsterdam Pharma Company NV
7 Dec 23
Shelf registration (foreign)
4:16pm
required to be disclosed in the Registration Statement or the Prospectus.
(ii) Anti-Corruption and Anti-Bribery Laws. Neither the Company nor any of its … Corrupt Practices Act of 1977, as amended (the “FCPA”), the UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law; or (iv
424B3
NAMS
NewAmsterdam Pharma Company NV
15 Aug 23
Prospectus supplement
4:52pm
, data corruption and significant disruption of our business operations, and could harm our reputation and subject us to liability, lawsuits and actions … -bribery and anti-money laundering laws in the jurisdictions in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit
POS AM
8rrq16hd
7 Aug 23
Prospectus update (post-effective amendment)
7:56am
6-K
EX-99.2
cpmxf075pi
7 Aug 23
Research and development expenses
7:24am
424B3
74zvh3 vbxx
9 Jun 23
Prospectus supplement
9:43pm
6-K
EX-1.1
rz4f205xae
9 Jun 23
Current report (foreign)
9:39pm
424B3
wtk1v9lgrvzlhuptld5
8 Jun 23
Prospectus supplement
5:01pm
424B3
q3dqavz1inypg72
6 Jun 23
Prospectus supplement
4:20pm
424B3
kaq5qxgb
25 Apr 23
Prospectus supplement
8:14am
POS AM
75ncm4mgs
17 Apr 23
Prospectus update (post-effective amendment)
9:09am
F-1
mh8ghuopxc
19 Dec 22
Registration statement (foreign)
6:22pm
6-K
EX-2.1
yut2xzws3
23 Nov 22
Current report (foreign)
4:36pm
424B3
g7ff f4dqj
18 Oct 22
Prospectus supplement
4:41pm
F-4/A
0238vu pb
13 Oct 22
Registration of securities (foreign) (amended)
5:18pm
F-4/A
bhdb5e3xtp6pjcsg8q
3 Oct 22
Registration of securities (foreign) (amended)
5:12pm
F-4/A
EX-10.9
8mvj7l0xyr5xdk7zj9
13 Sep 22
Registration of securities (foreign) (amended)
5:03pm